Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 317Glioblastoma 176Gliosarcoma 166Astrocytoma 125Brain Neoplasms 117Osteosarcoma 101Glioma 97Central Nervous System Neoplasms 96Oligodendroglioma 92Neuroblastoma 88Neoplasms 87Melanoma 87Breast Neoplasms 81Ovarian Neoplasms 70Lymphoma 67Dendritic Cell Sarcoma, Interdigitating 64Sarcoma, Ewing 63Rhabdomyosarcoma 63Recurrence 63Carcinoma, Non-Small-Cell Lung 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Burkitt Lymphoma 59Lymphoma, Non-Hodgkin 55Medulloblastoma 53Colorectal Neoplasms 53Wilms Tumor 52Pancreatic Neoplasms 51Neoplasm Metastasis 49Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Hepatocellular 44

Interventions

NVP-BKM120 1Imatinib Mesylate 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × 3rd Line GIST × Sarcoma × Clear all
NCT01468688 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
60 enrolled
Sarcoma

3rd Line GIST

NCT01735968 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
56 enrolled
Sarcoma

3rd Line GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡